These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12028031)

  • 1. Stevens-Johnson syndrome after treatment with STI571: a case report.
    Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
    Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
    Brouard MC; Prins C; Mach-Pascual S; Saurat JH
    Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sti571-induced Stevens-Johnson Syndrome.
    Vidal D; Puig L; Sureda A; Alomar A
    Br J Haematol; 2002 Oct; 119(1):274-5. PubMed ID: 12358937
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib-induced Stevens-Johnsons syndrome.
    Jha P; Himanshu D; Jain N; Singh AK
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pityriasis rosea associated with imatinib (STI571, Gleevec).
    Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
    Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose.
    Pavithran K; Thomas M
    Indian J Dermatol Venereol Leprol; 2005; 71(4):288-9. PubMed ID: 16394445
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous reactions to STI571.
    Brouard M; Saurat JH
    N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
    [No Abstract]   [Full Text] [Related]  

  • 9. Late onset imatinib-induced Stevens-Johnson syndrome.
    Bois E; Holle LM; Farooq U
    J Oncol Pharm Pract; 2014 Dec; 20(6):476-8. PubMed ID: 24399835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for imatinib mesylate therapy and clinical management.
    Guilhot F
    Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.
    Sirulink A; Silver RT; Najfeld V
    Leukemia; 2001 Nov; 15(11):1795-7. PubMed ID: 11681425
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
    Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
    J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
    Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema following imatinib mesylate.
    Duncan E; Raj K; Mufti G
    Br J Haematol; 2003 Jul; 122(1):1. PubMed ID: 12823338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.